AXM PHARMA INC
OOTC:AXMP0.00
USD
+0.00
(+9,900.00%)
ISIN
US0024571095
CUSIP
002457109
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
0.00
81.12
5Y
0.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Linda L. Forster
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 3651 Lindell Road Las Vegas NV United States 89103
- IPO Date
- Feb 2, 2001
- Website
- axmpharmainc.com
- Similar Companies
- Business
- AXM Pharma, Inc. is a pharmaceutical company primarily engaged in the manufacture, marketing, and distribution of proprietary and generic pharmaceutical products, including injectables, capsules, tablets, liquids, medicated skin products, complete lice treatment kits, cranberry tablets, chest congestion relief formulations, lice killing shampoo, and ear wax removal aids. The company operates mainly in the People's Republic of China and other international markets. Founded on June 24, 1999, AXM Pharma is headquartered in New York, New York, and conducts business through its wholly owned subsidiary Werke Pharmaceuticals, Inc., which fully owns Shenyang Tianwei Werke Pharmaceutical Co. AXM Pharma recently underwent major strategic changes including a change in ownership and leadership in 2018, when Emmanuel Neossi acquired 70% control of the company and was appointed Chairman, reflecting a strategic focus on vertical integration within key agribusiness sectors, especially the global cocoa market, which aligns with broader diversification efforts outside traditional pharmaceutical operations. The company continues expanding its product portfolio and market presence, emphasizing growth in pharmaceutical manufacturing and distribution within China and internationally. This includes recent operational shifts to meet evolving regulatory standards such as Chinese Good Manufacturing Practice (cGMP) compliance and growing demand for over-the-counter and prescription drugs. AXM Pharma's product offerings and strategic realignments position it as a diversified pharmaceutical entity with cross-industry interests and expansion initiatives across global markets.